PMID- 31605920
OWN - NLM
STAT- MEDLINE
DCOM- 20200803
LR  - 20200803
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 158
DP  - 2019 Oct-Nov
TI  - Adverse event and treatment completion rates of a 12-dose weekly isoniazid and 
      rifapentine course for South Korean healthcare workers.
PG  - 42-48
LID - S0954-6111(19)30307-5 [pii]
LID - 10.1016/j.rmed.2019.10.005 [doi]
AB  - PURPOSE: We investigated the adverse events (AEs) and treatment completion rates 
      of a 3 month course of once-weekly isoniazid and rifapentine (3H(1)P(1)) in South 
      Korean health care workers (HCWs) with latent tuberculosis infection (LTBI). 
      METHODS: HCWs who were candidates for LTBI treatment were enrolled from two 
      tertiary referral centers between December 2016 and October 2017. From December 
      2016 through March 2017, HCWs who agreed were treated with the 3H(1)P(1) regimen 
      (3H(1)P(1) group). Their compliance and AEs were prospectively collected. From 
      April 2017 onward, HCWs who required LTBI treatment received 3 months of 
      isoniazid plus rifampin (3HR group), and their medical records were 
      retrospectively reviewed. RESULTS: During the study period, 406 HCWs were 
      treated, 226 (55.7%) in the 3H(1)P(1) group, and 180 (44.3%) in the 3HR group. 
      The number of subjects with AEs was significantly greater in the 3H(1)P(1) group 
      (75.2% vs 56.7%, P < 0.001), in particular a flu-like syndrome (19.0% vs. 0%, 
      P < 0.001). However, hepatotoxicity occurred less frequently in those receiving 
      3H(1)P(1) (7.5% vs. 20.0%, P < 0.001). Per protocol definition, anaphylaxis 
      developed in 1.8% of the 3H(1)P(1) group. The overall treatment completion rate 
      was greater in the 3H(1)P(1) group (92.9% vs 86.7%, P = 0.036). CONCLUSIONS: The 
      3H(1)P(1) regimen had a higher treatment completion rate and lower hepatotoxicity 
      compared with the 3HR regimen. However, it resulted in a higher rate of flu-like 
      syndromes. Additionally, a few subjects had anaphylaxis, although there were no 
      fatalities.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Jo, Kyung-Wook
AU  - Jo KW
AD  - Division of Pulmonology and Critical Care Medicine, Department of Internal 
      Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 
      South Korea.
FAU - Kim, Ju Sang
AU  - Kim JS
AD  - Division of Pulmonary and Critical Care Medicine, Department of Internal 
      Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic 
      University of Korea, Incheon, South Korea.
FAU - Kwon, Hyouk-Soo
AU  - Kwon HS
AD  - Division of Allergy and Clinical Immunology, Department of Internal Medicine, 
      Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
FAU - Park, Yea Eun
AU  - Park YE
AD  - Division of Pulmonology and Critical Care Medicine, Department of Internal 
      Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 
      South Korea.
FAU - Kim, Ja Young
AU  - Kim JY
AD  - Office for Infection Control, Asan Medical Center, Seoul, South Korea.
FAU - Hong, Min Jee
AU  - Hong MJ
AD  - Office for Infection Control, Asan Medical Center, Seoul, South Korea.
FAU - Shim, Tae Sun
AU  - Shim TS
AD  - Division of Pulmonology and Critical Care Medicine, Department of Internal 
      Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 
      South Korea. Electronic address: shimts@amc.seoul.kr.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20191007
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Antitubercular Agents)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Refbp1 protein, mouse)
RN  - 0 (Transcription Factors)
RN  - V83O1VOZ8L (Isoniazid)
SB  - IM
MH  - Anaphylaxis/chemically induced
MH  - Antitubercular Agents/*administration & dosage/adverse effects
MH  - Female
MH  - *Health Personnel
MH  - Humans
MH  - Isoniazid/*administration & dosage/*adverse effects
MH  - Latent Tuberculosis/*drug therapy
MH  - Male
MH  - Occupational Health
MH  - RNA-Binding Proteins/*administration & dosage/*adverse effects
MH  - Republic of Korea
MH  - Time Factors
MH  - Transcription Factors/*administration & dosage/*adverse effects
OTO - NOTNLM
OT  - Adverse events
OT  - Anaphylaxis
OT  - Latent tuberculosis infection
OT  - Rifapentine
OT  - Treatment completion
EDAT- 2019/10/13 06:00
MHDA- 2020/08/04 06:00
CRDT- 2019/10/13 06:00
PHST- 2019/07/26 00:00 [received]
PHST- 2019/09/28 00:00 [revised]
PHST- 2019/10/06 00:00 [accepted]
PHST- 2019/10/13 06:00 [pubmed]
PHST- 2020/08/04 06:00 [medline]
PHST- 2019/10/13 06:00 [entrez]
AID - S0954-6111(19)30307-5 [pii]
AID - 10.1016/j.rmed.2019.10.005 [doi]
PST - ppublish
SO  - Respir Med. 2019 Oct-Nov;158:42-48. doi: 10.1016/j.rmed.2019.10.005. Epub 2019 
      Oct 7.